Literature DB >> 20042615

Application of truncated immunodominant polypeptide from hepatitis E virus (HEV) ORF2 in an assay to exclude nonspecific binding in detecting anti-HEV immunoglobulin M.

Jin-Shun Pan1, Kui Zhang, Jinyong Zhou, Chao Wu, Hui Zhuang, Yi-Hua Zhou.   

Abstract

The diagnosis of recent hepatitis E virus (HEV) infection depends on serologic testing for anti-HEV IgM; however, false-positive results may occur. In the present study, we cloned the ORF2 fragment of genotype 4 HEV and demonstrated that a subregion covering amino acids 459 to 607 in ORF2 forms the immunodominant B-cell epitopes, as it does in genotype 1 viruses. Truncation of several residues from either the N or C terminus of the polypeptide abolished the reactivity of anti-HEV from naturally infected persons. By the combination of high reactivity of the immunodominant polypeptide and poor reactivity of the truncated polypeptide, we established an indirect enzyme-linked immunosorbent assay (ELISA) to detect anti-HEV IgM. In this assay, all 37 sera that were HEV RNA positive reacted with the immunodominant polypeptide but not with the truncated one, and none of 159 sera from healthy persons reacted with either of the polypeptides. In retesting of 117 sera that originally tested positive for anti-HEV IgM, using a Genelabs kit, only 34 were positive and 83 were negative. Western blot analyses and other experiments strongly indicated that these 83 discordant sera were negative for anti-HEV IgM. Furthermore, among the 117 sera, 5 reacted with both the immunodominant and truncated polypeptides, with comparable optical densities at 450 nm. However, their reactivity was demonstrated to result from nonspecific binding. Together, the data indicate that the poor reactivity of a truncated ORF2 polypeptide can be used to exclude nonspecific binding in the detection of anti-HEV IgM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042615      PMCID: PMC2832410          DOI: 10.1128/JCM.01671-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Solid-phase enzyme-linked immunosorbent assay for hepatitis E virus IgG and IgM antibodies utilizing recombinant antigens and synthetic peptides.

Authors:  G J Dawson; K H Chau; C M Cabal; P O Yarbough; G R Reyes; I K Mushahwar
Journal:  J Virol Methods       Date:  1992-07       Impact factor: 2.014

2.  A divergent genotype of hepatitis E virus in Chinese patients with acute hepatitis.

Authors:  Y Wang; R Ling; J C Erker; H Zhang; H Li; S Desai; I K Mushahwar; T J Harrison
Journal:  J Gen Virol       Date:  1999-01       Impact factor: 3.891

3.  Evaluation of a new rapid immunochromatographic assay for serodiagnosis of acute hepatitis E infection.

Authors:  Khin S A Myint; Ming Guan; Hsiao Ying Chen; Yang Lu; David Anderson; Teresa Howard; Harald Noedl; Mammen P Mammen
Journal:  Am J Trop Med Hyg       Date:  2005-11       Impact factor: 2.345

4.  Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid.

Authors:  Shao-Wei Li; Jun Zhang; Zhi-Qiang He; Ying Gu; Ru-Shi Liu; Jian Lin; Yi-Xin Chen; Mun-Hon Ng; Ning-Shao Xia
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

5.  Comparison of a new immunochromatographic test to enzyme-linked immunosorbent assay for rapid detection of immunoglobulin m antibodies to hepatitis e virus in human sera.

Authors:  Hsiao Ying Chen; Yang Lu; Teresa Howard; David Anderson; Priscilla Yiquan Fong; Wei-Ping Hu; Chee Poh Chia; Ming Guan
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

6.  An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4.

Authors:  Yi-Hua Zhou; Robert H Purcell; Suzanne U Emerson
Journal:  Vaccine       Date:  2004-06-30       Impact factor: 3.641

7.  Evaluation of anti-hepatitis E virus (HEV) immunoglobulin A in a serological screening for HEV infection.

Authors:  Abeer Elkady; Yasuhito Tanaka; Fuat Kurbanov; Noboru Hirashima; Masaya Sugiyama; Anis Khan; Hideaki Kato; Akihiko Okumura; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

8.  Differential diagnosis of hepatitis E virus, cytomegalovirus and Epstein-Barr virus infection in patients with suspected hepatitis E.

Authors:  M Fogeda; F de Ory; A Avellón; J M Echevarría
Journal:  J Clin Virol       Date:  2009-06-07       Impact factor: 3.168

9.  Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response.

Authors:  R Bendall; V Ellis; S Ijaz; P Thurairajah; H R Dalton
Journal:  J Med Virol       Date:  2008-01       Impact factor: 2.327

10.  Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine.

Authors:  Darren J Schofield; Robert H Purcell; Hanh T Nguyen; Suzanne U Emerson
Journal:  Vaccine       Date:  2003-12-12       Impact factor: 3.641

View more
  3 in total

1.  Restricted enzooticity of hepatitis E virus genotypes 1 to 4 in the United States.

Authors:  Chen Dong; Jihong Meng; Xing Dai; Jiu-Hong Liang; Alicia R Feagins; Xiang-Jin Meng; Natalia M Belfiore; Carol Bradford; Joseph L Corn; Carolyn Cray; Gregory E Glass; Melvin L Gordon; Richard A Hesse; Donald L Montgomery; William L Nicholson; Anthony A Pilny; Sheela Ramamoorthy; Douglas D Shaver; Jan Drobeniuc; Michael A Purdy; Howard A Fields; Saleem Kamili; Chong-Gee Teo
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

2.  A single amino acid substitution changes antigenicity of ORF2-encoded proteins of hepatitis E virus.

Authors:  Jiu-Hong Liang; Xing Dai; Chen Dong; Ji-Hong Meng
Journal:  Int J Mol Sci       Date:  2010-08-12       Impact factor: 5.923

3.  Hepatitis E virus seroprevalence in pregnant women in Jiangsu, China, and postpartum evolution during six years.

Authors:  Guangyu Gu; Hongyu Huang; Le Zhang; Yongchun Bi; Yali Hu; Yi-Hua Zhou
Journal:  BMC Infect Dis       Date:  2015-12-09       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.